22123-Urothelial Cancer-NA-289

Urothelial Cancer

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/ metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours. (1403-0011)

  • Details

ClinicalTrials.gov ID: NCT05512377
Diagnosis Type: NA
USOR Number:

  • Address

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

Search by practice name, trial titles, indicators and specific disease types.